Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,819 matching trials from the live ClinicalTrials.gov search.
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Autologous Umbilical Cord Blood
Biological
Lead sponsor
Michael Cotten
Other
Eligibility
Up to 2 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Conditions
Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
Interventions
N-Acetyl-L-Leucine, Placebo
Drug · Other
Lead sponsor
IntraBio Inc
Industry
Eligibility
4 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Active, not recruiting No phase listed Observational

MIRACLE of LIFE Study

NCT06074601
Conditions
Preterm Labor, Preterm Birth, Preterm Birth Complication, Preterm Premature Rupture of Membrane, Preeclampsia, HELLP, Gestational Hypertension, Gestational Diabetes Mellitus in Pregnancy, Small for Gestational Age at Delivery, Intrauterine Growth Restriction
Interventions
Mirvie Predictive Test for Adverse Pregnancy Outcomes
Diagnostic Test
Lead sponsor
Mirvie
Industry
Eligibility
18 Years and older · Female only
Enrollment
10,000 participants
Timeline
2021 – 2025
U.S. locations
10
States / cities
San Diego, California • Orlando, Florida • New Orleans, Louisiana + 7 more
Conditions
Congenital Heart Disease, Single Ventricle
Interventions
THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional

PK/PD of Digoxin in Infants With SVHD

NCT06613477
Conditions
Single-ventricle, Infant Conditions, Infant, Newborn, Diseases, Infant, Premature, Diseases
Interventions
PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Days to 6 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Durham, North Carolina • Charleston, South Carolina
Conditions
Congenital Heart Disease, Sepsis, Infection
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 5 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Disseminated Neuroblastoma, Malignant Neoplasm, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Mixed Germ Cell Tumor, Ovarian Monodermal and Highly Specialized Teratoma, Ovarian Polyembryoma, Ovarian Yolk Sac Tumor, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Testicular Choriocarcinoma, Testicular Choriocarcinoma and Embryonal Carcinoma, Testicular Choriocarcinoma and Seminoma, Testicular Choriocarcinoma and Teratoma, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma, Testicular Embryonal Carcinoma and Seminoma, Testicular Embryonal Carcinoma and Teratoma, Testicular Embryonal Carcinoma and Teratoma With Seminoma, Testicular Embryonal Carcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor, Testicular Yolk Sac Tumor and Teratoma, Testicular Yolk Sac Tumor and Teratoma With Seminoma
Interventions
ipilimumab, therapeutic allogeneic lymphocytes
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Infantile Hemangiomas
Interventions
Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 8 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Congenital Heart Disease, Cardiopulmonary Bypass
Interventions
Acetaminophen
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Day to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Williams Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Shprintzen Syndrome, Smith-Magenis Syndrome, DiGeorge Syndrome, Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gout, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
21 Years and older
Enrollment
24,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Nasal Obstruction, Septal Defect, Allergic Rhinitis, Nasal Polyps, Nasal Valve Collapse
Interventions
Batten batten graft, Septoplasty, Inferior Turbinate Reduction
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Poplar Bluff, Missouri • New York, New York • Staten Island, New York
Withdrawn Not applicable Interventional

Partial Heart Transplantation

NCT06055556
Conditions
Congenital Heart Disease
Interventions
Partial Heart Transplantation, Freshly procured valve
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
Up to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Study of Heritable Connective Tissue Disorders

NCT00001641
Conditions
Connective Tissue Disease, Dissecting Aneurysm, Ehlers Danlos Syndrome, Marfan Syndrome, Nail Patella Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 99 Years
Enrollment
32,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2032
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Conditions
Congenital Heart Disease
Interventions
Gadopiclenol, Gadobenate dimeglumine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Conditions
Hypoplastic Left Heart Syndrome, Obstructive Sleep Apnea Syndrome, Single Ventricle Physiology
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
1 Month to 2 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, New York
Conditions
Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more